NDAORALTABLET
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
LANOXIN (digoxin) by Pfizer is digoxin's actions are mediated through its effects on na-k atpase. First approved in 1997.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LANOXIN (digoxin) is a cardiac glycoside oral tablet approved in 1997 for atrial fibrillation. It works by inhibiting the Na-K ATPase pump, increasing intracellular calcium in the myocardium to enhance contractility while slowing heart rate and AV node conduction. The drug indirectly stimulates parasympathetic activity and reduces sympathetic outflow, producing positive inotropic and negative chronotropic effects.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30), teams are focused on lifecycle management and brand retention rather than growth expansion.
Mechanism of Action
digoxin's actions are mediated through its effects on Na-K ATPase. This enzyme, the "sodium pump," is responsible for maintaining the intracellular milieu throughout the body by moving sodium ions out of and potassium ions into cells. By inhibiting Na-K ATPase, digoxin causes increased availability…
Pharmacologic Class:
Cardiac Glycoside
Indications
Worked on LANOXIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.